NCT03945760 is a EARLY_PHASE1 clinical trial of Baricitinib in Allergic Contact Dermatitis, sponsored by Wright State Physicians.

Who is sponsoring NCT03945760?

NCT03945760 is sponsored by Wright State Physicians.

What drugs are being tested in NCT03945760?

Interventions in NCT03945760: Baricitinib, Placebo.

What condition does NCT03945760 study?

NCT03945760 studies Allergic Contact Dermatitis.

Is NCT03945760 still recruiting?

NCT03945760 is currently completed. Last updated 5 December 2023.

Last reviewed 2023-12-05 · How we verify

NCT03945760

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects

Completed EARLY_PHASE1 Last updated 5 December 2023

What this trial tests

EARLY_PHASE1 trial testing Baricitinib in Allergic Contact Dermatitis in 23 participants. Completed in 16 October 2023.

Timeline

14 September 2020

Primary endpoint
16 October 2023

16 October 2023

Quick facts

Lead sponsor	Wright State Physicians
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	23
Start date	14 September 2020
Primary completion	16 October 2023
Estimated completion	16 October 2023
Sites	1 location across United States

Drugs / interventions tested

Baricitinib (baricitinib) — full drug profile →
Placebo

Conditions studied

Allergic Contact Dermatitis — all drugs for Allergic Contact Dermatitis →

Sponsor

Wright State Physicians

Who can join

Adults 18 to 40, male only, with Allergic Contact Dermatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The treatment of allergic contact dermatitis (ACD) can be unsatisfactory, and that other skin diseases such as atopic dermatitis have an increased likelihood of ACD, improved systemic treatments are needed. This research study explores the effectiveness of Baricitinib in treating Delayed-Type Hypersensitivity (allergic) versus Irritant Skin reactions. Subjects for this study need to be healthy males between the ages of 18 and 40. This study will evaluate this by injecting antigens as well as applying them on top of the skin to the forearm then measure the effects of Baricitinib by skin and blood testing.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens.
Hu Q, Bian Q, Rong D, Wang L, et al · · 2023 · cited 190× · PMID 36911202 · DOI 10.3389/fbioe.2023.1110765
JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition.
Luo Y, Alexander M, Gadina M, O'Shea JJ, et al · · 2021 · cited 92× · PMID 34625141 · DOI 10.1016/j.jaci.2021.08.004

Verify or expand the search:

Other trials of Baricitinib

Trials testing the same drug.

NCT07543458 — Therapeutics for Moderate and Severe Dengue · Phase 3 · not yet recruiting
NCT06381661 — Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Tra · Phase 2 · not yet recruiting
NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
NCT07268534 — Biologics in Folliculitis Decalvans : an Adaptative Trial Research · Phase 2 · not yet recruiting
NCT06923072 — Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement · Phase 2 · recruiting

Other recruiting trials for Allergic Contact Dermatitis

Currently open trials in the same condition.

NCT06529913 — Environmental Exposure to Heavy Metals, Nanoparticles, and Emergent Contaminants and Risk of Allergic Diseases · NA · recruiting
NCT05535738 — Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation · Phase 2, PHASE3 · recruiting
NCT03935971 — The Effects of Dupilumab on Allergic Contact Dermatitis · Phase 4 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03945760 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wright State Physicians
Last refreshed: 5 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03945760.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing